Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic MedicationGlobeNewsWire • 09/10/20
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?Zacks Investment Research • 09/03/20
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/20
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal OriginGlobeNewsWire • 07/28/20
Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian CancerGlobeNewsWire • 07/23/20
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic CancerGlobeNewsWire • 06/30/20
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual MeetingGlobeNewsWire • 06/15/20
Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 05/14/20
Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS RatingInvestors Business Daily • 05/06/20
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/05/20
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/04/20